论文部分内容阅读
目的探讨坎地沙坦联合阿托伐他汀治疗早期糖尿病肾病对患者血清脂联素的影响程度。方法选取2014年4月至2015年4月我院收治的早期糖尿病肾病患者120例以及对照早期糖尿病肾病患者30例,将其分别划分为观察组以及对照组,对观察组患者实施坎地沙坦联合阿托伐他汀治疗,对照组实施常规治疗,观察两组的脂联素情况。结果观察组患者与对照组患者的肾功能Scr、SBp、DBp、胱抑素Cys、尿蛋白排泄率与脂联素有明显差异,存在统计学意义(P<0.05)。结论坎地沙坦药物联合阿托伐他汀药物治疗早期的糖尿病肾病可以改善患者的糖脂代谢情况,有效降低患者的脂联素以及血清中的胱抑素水平,在早期糖尿病肾病的临床治疗上存在重要意义。
Objective To investigate the effect of candesartan combined with atorvastatin on serum adiponectin in patients with early diabetic nephropathy. Methods From April 2014 to April 2015, 120 patients with early diabetic nephropathy admitted to our hospital and 30 patients with early diabetic nephropathy were selected and divided into observation group and control group respectively. Patients in observation group were treated with candesartan Combined with atorvastatin treatment, the control group to implement conventional treatment, observation of two groups of adiponectin. Results The renal function Scr, SBp, DBp, Cystatin Cys, urinary protein excretion rate and adiponectin in observation group and control group were significantly different (P <0.05). Conclusion The combination of candesartan and atorvastatin can improve glycemic and lipid metabolism in patients with early diabetic nephropathy and reduce adiponectin and serum levels of cystatin in patients with early diabetic nephropathy There is an important meaning.